FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034038962> ?p ?o ?g. }

• W2034038962 endingPage "11750" @default.
• W2034038962 startingPage "11741" @default.
• W2034038962 abstract "Cetuxiamb, a monoclonal antibody against epidermal growth factor receptor (EGFR), has been used in combination with chemotherapy for patients with metastatic colorectal cancer (mCRC). However, the efficacy of combined therapies of cetuximab and different chemotherapy regimens remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and toxicity of adding cetuximab to oxaliplatin-based or irinotecan-based chemotherapeutic regimens for the treatment of patients with mCRC with wild-type/mutated KRAS tumors. Randomized controlled trials (RCTs), published in Pubmed and Embase were systematically reviewed to assess the survival benefits and toxicity profile mCRC patients treated with cetuximab plus chemotherapy. Outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicities. Results were expressed as the hazard ratio (HR) with 95 % confidence intervals (CI). Pooled estimates were generated by using a fixed-effects model or a randomized-effects model, depending on the heterogeneity among studies. A total of 12 trials involving 6,297 patients met the inclusion criteria and were included in this meta-analysis. All patients were administered oxaliplatin-based or irinotecan-based chemotherapy with or without cetuximab. Pooled results showed that the addition of cetuximab did not significantly improve the OS (HR = 0.99, 95 % CI = 0.89–1.09; Z = 0.28, P = 0.78) or PFS (HR = 0.94, 95 % CI = 0.81–1.10; Z = 0.76, P = 0.49), but did improve ORR (RR = 1.34, 95 % CI = 1.08–1.65; Z = 2.72, P = 0.00), when compared with chemotherapy alone. Subgroup analysis showed the highest PFS benefit in patients with wild-type KRAS tumors (HR = 0.80, 95 % CI = 0.65–0.99; Z = 2.1, P = 0.04) or wild-type KRAS/BRAF tumors (HR = 0.64, 95 % CI = 0.52–0.79; Z = 4.15, P = 0.00). When combined with cetuximab, irinotecan-based chemotherapy was significantly associated with prolonged PFS (HR = 0.79, 95 % CI = 0.66–0.96; Z = 2.36, P = 0.02) for all patients with differing gene-status. The incidence of grade 3/4 adverse events, including skin toxicity, diarrhea, hypertension, anorexia, and mucositis/stomatitis, was slightly higher in the combined therapy group than in the chemotherapy-only group. Based on the current evidence, the addition of cetuximab to chemotherapy significantly improves the PFS in patients with wild-type KRAS or wild-type KRAS/BRAF tumors as well as the ORR in all patients. In addition, irinotecan-based combination therapy showed a beneficial effect on the PFS in all patients. These findings confirm the use of cetuximab in combination with chemotherapy for the treatment of patients with mCRC with wild-type KRAS tumors. Further multi-center RCTs are needed to indentify these findings." @default.
• W2034038962 created "2016-06-24" @default.
• W2034038962 creator A5020078006 @default.
• W2034038962 creator A5022626401 @default.
• W2034038962 creator A5026546402 @default.
• W2034038962 date "2014-11-23" @default.
• W2034038962 modified "2023-09-26" @default.
• W2034038962 title "Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials" @default.
• W2034038962 cites W141482010 @default.
• W2034038962 cites W1480729244 @default.
• W2034038962 cites W1874410314 @default.
• W2034038962 cites W1964435302 @default.
• W2034038962 cites W1971366462 @default.
• W2034038962 cites W1972813927 @default.
• W2034038962 cites W1981033218 @default.
• W2034038962 cites W1986215651 @default.
• W2034038962 cites W2006824814 @default.
• W2034038962 cites W2007649418 @default.
• W2034038962 cites W2016206649 @default.
• W2034038962 cites W2038693293 @default.
• W2034038962 cites W2043911313 @default.
• W2034038962 cites W2047138772 @default.
• W2034038962 cites W2049282019 @default.
• W2034038962 cites W2049484790 @default.
• W2034038962 cites W2069368662 @default.
• W2034038962 cites W2070975285 @default.
• W2034038962 cites W2072617189 @default.
• W2034038962 cites W2087088052 @default.
• W2034038962 cites W2087510570 @default.
• W2034038962 cites W2088095316 @default.
• W2034038962 cites W2095201384 @default.
• W2034038962 cites W2096122707 @default.
• W2034038962 cites W2098354753 @default.
• W2034038962 cites W2100471896 @default.
• W2034038962 cites W2104580737 @default.
• W2034038962 cites W2106787323 @default.
• W2034038962 cites W2107328434 @default.
• W2034038962 cites W2110097275 @default.
• W2034038962 cites W2123265037 @default.
• W2034038962 cites W2123548341 @default.
• W2034038962 cites W2125435699 @default.
• W2034038962 cites W2127640925 @default.
• W2034038962 cites W2128403792 @default.
• W2034038962 cites W2129255527 @default.
• W2034038962 cites W2130948044 @default.
• W2034038962 cites W2131413118 @default.
• W2034038962 cites W2132352600 @default.
• W2034038962 cites W2134142320 @default.
• W2034038962 cites W2134338262 @default.
• W2034038962 cites W2139168548 @default.
• W2034038962 cites W2142564546 @default.
• W2034038962 cites W2143847499 @default.
• W2034038962 cites W2144425748 @default.
• W2034038962 cites W2145070131 @default.
• W2034038962 cites W2150000105 @default.
• W2034038962 cites W2154188825 @default.
• W2034038962 cites W2155311724 @default.
• W2034038962 cites W2156700619 @default.
• W2034038962 cites W2157824687 @default.
• W2034038962 cites W2166609912 @default.
• W2034038962 cites W2315123323 @default.
• W2034038962 cites W2414639108 @default.
• W2034038962 cites W2589790637 @default.
• W2034038962 cites W4244082907 @default.
• W2034038962 doi "https://doi.org/10.1007/s13277-014-2227-z" @default.
• W2034038962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25417200" @default.
• W2034038962 hasPublicationYear "2014" @default.
• W2034038962 type Work @default.
• W2034038962 sameAs 2034038962 @default.
• W2034038962 citedByCount "20" @default.
• W2034038962 countsByYear W20340389622014 @default.
• W2034038962 countsByYear W20340389622015 @default.
• W2034038962 countsByYear W20340389622016 @default.
• W2034038962 countsByYear W20340389622017 @default.
• W2034038962 countsByYear W20340389622018 @default.
• W2034038962 countsByYear W20340389622019 @default.
• W2034038962 countsByYear W20340389622020 @default.
• W2034038962 countsByYear W20340389622021 @default.
• W2034038962 countsByYear W20340389622022 @default.
• W2034038962 countsByYear W20340389622023 @default.
• W2034038962 crossrefType "journal-article" @default.
• W2034038962 hasAuthorship W2034038962A5020078006 @default.
• W2034038962 hasAuthorship W2034038962A5022626401 @default.
• W2034038962 hasAuthorship W2034038962A5026546402 @default.
• W2034038962 hasConcept C121608353 @default.
• W2034038962 hasConcept C126322002 @default.
• W2034038962 hasConcept C143998085 @default.
• W2034038962 hasConcept C168563851 @default.
• W2034038962 hasConcept C207103383 @default.
• W2034038962 hasConcept C2776694085 @default.
• W2034038962 hasConcept C2779998722 @default.
• W2034038962 hasConcept C2780259306 @default.
• W2034038962 hasConcept C2780962732 @default.
• W2034038962 hasConcept C2781187634 @default.
• W2034038962 hasConcept C44249647 @default.
• W2034038962 hasConcept C526805850 @default.
• W2034038962 hasConcept C71924100 @default.
• W2034038962 hasConcept C95190672 @default.

• next